Rare diseases
Investigational molecules
Locations
Study of BDC-1001 and Nivolumab for Patients with Advanced HER2-Positive Solid Tumors
FranceStudy on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy
GermanyStudy of Nivolumab and Entinostat for Children and Adolescents with High-Risk Refractory or Relapsed Malignant Disease
AustriaStudy of Nivolumab and Ipilimumab for Patients with Advanced Kidney Cancer and Intermediate or Poor Risk Factors
AustriaStudy of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery
AustriaStudy of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression
AustriaStudy on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors
AustriaStudy of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation
AustriaStudy of Nivolumab and Ipilimumab for Patients with Advanced Liver Cancer (Hepatocellular Carcinoma) as First-Line Treatment
AustriaStudy Comparing Nivolumab and Ipilimumab with Chemotherapy to Chemotherapy Alone for Patients with Stage IV Non-Small Cell Lung Cancer
BelgiumStudy on Nivolumab and Ipilimumab for Patients with Untreated Unresectable or Metastatic Urothelial Cancer
CzechiaStudy of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
